Tag: sanofi

Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- ...

Sanofi today unveiled a new bold and unifying corporate brand that supports the modernization and transformation ...

Sanofi is partnering with leading groups delivering practice-changing breast cancer research, the Breast International Group (BIG), ...

As part of a long-standing commitment to reduce the environmental footprint of the company’s products and ...

A pivotal Phase 2/3 study of venglustat in autosomal dominant polycystic kidney disease (ADPKD) did not ...

Two-stage design will evaluate vaccine formulations targeting original D.614 virus as well as B.1.351 variant, in diverse geographies with multiple circulating variants A booster study ...

Libtayo recommended for approval in the first-line treatment of certain patients with advanced non-small cell lung ...

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups High immune response after a single dose in patients with prior ...

Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine. Together, the ...

Nirsevimab is being investigated as a first-in-class single dose immunization to provide protection for all infants entering their first RSV season. Nirsevimab met its Phase ...